New strategies for allergen-specific immunotherapy have focused on reducing IgE reactivity of purified recombinant allergens while maintaining T-cell epitopes. Previously, we showed that disrupting the disulfide bonds of the major house dust mite allergen Der p 2 resulted in 10 -100-fold less skin test reactivity in miteallergic subjects but did not change in vitro T-cell proliferative responses. To provide a more complete picture of the antigenic surface of Der p 2, we report here the identification of three epitopes using hydrogen protection nuclear magnetic resonance spectroscopy. The epitopes are defined by monoclonal antibodies that are able to inhibit IgE antibody binding to the allergen. Each monoclonal antibody affected the amide exchange rate of 2-3 continuous residues in different regions of Der p 2. Based on these data, a number of other residues were predicted to belong to each epitope, and this prediction was tested for monoclonal antibody 7A1 by generating alanine point mutants. The results indicate that only a small number of residues within the predicted epitope are functionally important for antibody binding. The molecular definition of these three epitopes will enable us to target limited positions for mutagenesis and to expand our studies of hypoallergenic variants for immunotherapy.Epidemiologic studies suggest that between 10 and 20% of the world population exhibits some form of IgE-mediated hypersensitivity, which is manifested as asthma, atopic dermatitis, or allergic rhinitis (1). A number of studies have shown that sensitivity to house dust mite allergens is the most important risk factor for asthma (1, 2). More than 10 mite allergens have been defined, and the 14-kDa Group 2 allergens (Der p 2 1 and Der f 2) are considered major allergens because of the fact that 80 -90% of patients have specific IgE Ab to these allergens (3).Previously we reported that Der p 2 is structurally a member of the immunoglobulin superfamily, although the function of the allergen remains unknown (4).Therapy for allergic disease includes allergen avoidance, pharmacotherapy, and allergen-specific immunotherapy. Recently, new strategies for immunotherapy have been proposed with the aim of improving efficacy, patient compliance, and associated risks (5). Our studies have focused on the generation of hypoallergenic variants; the underlying hypothesis is that reducing IgE reactivity will reduce IgE-mediated side effects (6). The mapping of epitopes on Der p 2 and Der f 2 is an important step toward the development of hypoallergenic variants. Using murine mAb and sera from mite-allergic subjects, we have shown that the epitopes on the Group 2 allergens are conformational and that the three disulfide bonds stabilize this structure (6, 7). Mutational analysis of surface residues found that substitution of threonine for lysine at position 100 had reduced avidity for mAb 7A1, and mutations of residues 44 -46 affected the avidity of a second mAb, ␣DpX (8). A third mAb, 6D6, belongs to a group of mAb that recognize the di...